Guardant Health (NASDAQ:GH) Releases Quarterly Earnings Results, Misses Estimates By $0.15 EPS

Guardant Health (NASDAQ:GH) posted its quarterly earnings data on Thursday. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.15), Zacks reports. The company had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. Guardant Health updated its FY 2025 guidance to EPS.

Guardant Health Stock Performance

GH stock traded down $4.31 on Friday, reaching $43.09. The company’s stock had a trading volume of 2,623,807 shares, compared to its average volume of 2,471,443. The business has a fifty day simple moving average of $40.03 and a two-hundred day simple moving average of $31.51. Guardant Health has a 12-month low of $15.81 and a 12-month high of $50.89. The firm has a market cap of $5.32 billion, a PE ratio of -10.17 and a beta of 1.32.

Insider Buying and Selling

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of the stock in a transaction on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the transaction, the director now owns 2,676 shares in the company, valued at approximately $93,660. This represents a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 2,652 shares of company stock valued at $93,192 over the last quarter. 5.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on GH shares. Barclays started coverage on shares of Guardant Health in a research report on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 price objective on the stock. Raymond James reaffirmed an “outperform” rating and issued a $59.00 target price (up previously from $39.00) on shares of Guardant Health in a research note on Friday. Guggenheim reaffirmed a “buy” rating on shares of Guardant Health in a research note on Wednesday, January 22nd. The Goldman Sachs Group upped their target price on Guardant Health from $36.00 to $49.00 and gave the stock a “buy” rating in a research note on Tuesday, January 28th. Finally, Sanford C. Bernstein cut their target price on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research note on Wednesday, October 30th. Eighteen investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $44.39.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.